Assembled from the company's filings and exchange data as of today. Download PDF renders this page on the server; the narrative sections arrive with the Nexa composer.
Dossier · GlobalSpace Technologies Limit · 9 October 2026Page 1 of 3
Company Dossier
MarketPing Research · factual · no rating expressed
GlobalSpace Technologies Limit
BSE: 540654
BSE: 540654
Healthcare › Healthcare › Healthcare Services › Healthcare Research, Analytics & Technology
GlobalSpace Technologies Limit
StateQ4 FY26 filed
Last close · 8 Oct 2026₹36.90
Market cap₹0.1k cr
TTM P/E · P/B · EV/EBITDA41.5 · 2.23 · 27.6
GlobalSpace Technologies Limit is a Healthcare Services company. The annual-report business brief for this company has not been generated yet; the numbers below are as filed.
What a broker report prints here — the analyst's thesis. This dossier prints the filed record instead; the narrative read of the latest results, the guidance ledger and the earnings-call summary are the composer's sections (INSTITUTIONAL-PLAN.md M3) and are not yet produced.
Exhibit 1: Financial summary, FY20–FY26 (all audited; no estimate years)
| ₹ crore · consolidated | FY20 | FY21 | FY22 | FY25 | FY26 |
|---|---|---|---|---|---|
| Revenue | 26 | 27 | 13,28,861 | 43 | 51 |
| EBITDA (ex other income) | 7 | 10 | 6,90,107 | 1 | 4 |
| margin % | 25.4 | 37.6 | 51.9 | 2.2 | 8.4 |
| Owners' profit | 3 | 6 | 55,410 | (2) | 3 |
| EPS, as reported (₹) | 2.49 | 5.19 | 0.48 | 1.75 | 2.49 |
| ROE % · ROCE % | 8.5 · 15.1 | 15.9 · 19.6 | 1.9 · 4.9 | (3.7) · (2.4) | 5.0 · 5.0 |
| Debt / equity (x) | 0.18 | 0.12 | 0.73 | 0.18 | 0.06 |
| Cash from operations | — | 9 | (2,34,902) | 8 | 22 |
| Capex | — | 0 | 0 | (4) | (15) |
Source: SEBI results XBRL as filed with BSE/NSE; EBITDA excludes other income.
Every figure is a filed number or a ratio over filed numbers · No rating, target or fair value is expressed · Disclosures on the last pagemarketping.in
Dossier · GlobalSpace Technologies Limit · 9 October 2026Page 2 of 3
Exhibit 2: Quarterly performance, last 8 quarters
| ₹ crore | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 10 | 12 | 13 | 9 | 9 | 10 | 17 | 16 |
| Profit before tax | (3) | 0 | 1 | (0) | 0 | 0 | 1 | 0 |
| Net profit | (3) | 0 | 1 | (0) | 0 | (0) | 0 | 2 |
| EPS (₹) | (2.25) | 0.05 | 0.20 | 0.25 | 0.05 | 0.05 | 0.11 | 0.68 |
Source: quarterly results as filed; the balance sheet is filed half-yearly and is not repeated here.
Exhibit 3: Peers — basic industry group, by market cap
| Company | M.cap ₹ cr | P/E | P/B | EV/EBITDA | ROE % | ROCE % | Rev CAGR 5y % | EBITDA m. % |
|---|---|---|---|---|---|---|---|---|
| Jeevan Scientific Technology L | 165 | 196.9 | 2.26 | 16.0 | 1.4 | 2.4 | 5.1 | 21.5 |
| NOVELIX PHARMACEUTICALS LIMITE | 160 | — | 21.54 | — | (3.3) | (3.3) | — | (9.5) |
| GlobalSpace Technologies Limit ◆ | 127 | 41.5 | 2.23 | 27.6 | 5.0 | 3.4 | 13.7 | 7.1 |
| Adeshwar Meditex Limited | 23 | 21.7 | — | — | — | — | — | — |
| Vanta Bioscience Limited | 15 | 3.3 | — | — | — | 0.0 | (29.0) | — |
Source: exchange data and filed statements via the screener; multiples at current prices.
Exhibit 4: Where the company sits in its group
| Metric | Company | Group median | Rank | Better than |
|---|---|---|---|---|
| P/E (TTM) | 41.5 | 37.2 | 34 of 63 | 47% |
| P/B | 2.2 | 5.2 | 18 of 57 | 68% |
| ROCE | 3.5 | 8.0 | 47 of 69 | 32% |
| ROE | 5.0 | 9.1 | 39 of 57 | 32% |
| Debt / Equity | 0.1 | 0.1 | 23 of 56 | 60% |
| EBITDA margin | 7.1 | 21.5 | 47 of 57 | 18% |
| Revenue growth | 83.3 | 20.2 | 6 of 57 | 91% |
| Profit growth | 1247.8 | 11.4 | 1 of 55 | 100% |
| Market cap | 127 | 244 | 45 of 71 | 37% |
Source: MarketPing peer ranks; a rank is a measurement, not a view.
Every figure is a filed number or a ratio over filed numbers · No rating, target or fair value is expressed · Disclosures on the last pagemarketping.in
Dossier · GlobalSpace Technologies Limit · 9 October 2026Page 3 of 3
Exhibit 5: Filings of the last 90 days, with the measured price reaction
| Date · filing | Category | Importance | 1-day % | 5-day % |
|---|---|---|---|---|
| 1 Oct 2026 · AGM approves re-appointment of Independent Director and Managing Director | management changes | medium | — | — |
| 1 Oct 2026 · AGM approves re-appointment of Independent Director and Managing Director | management changes | medium | — | — |
| 1 Oct 2026 · AGM results: all 6 resolutions passed with strong majority | compliance | minimal | — | — |
| 29 Sept 2026 · GlobalSpace Technologies 16th AGM: all 6 resolutions passed | board shareholder meetings | medium | — | — |
| 25 Sept 2026 · Trading Window Closure from Oct 1 for Q2 FY26 Results | compliance | minimal | — | — |
| 6 Sept 2026 · 16th AGM scheduled for Sep 29, 2026 via video conferencing | compliance | minimal | — | — |
| 5 Sept 2026 · AGM notice and FY26 Annual Report sent to members without registered email | compliance | minimal | — | — |
| 5 Sept 2026 · GlobalSpace Technologies files Annual Report for FY 2025-26 | results | high | — | — |
| 5 Sept 2026 · 16th AGM Notice on Sept 29, 2026 - Six Resolutions Including MD Re-appointment | board shareholder meetings | low | — | — |
| 3 Sept 2026 · Newspaper ad of 16th AGM notice and remote e-voting details | compliance | minimal | — | — |
Source: exchange announcements; reaction = close-to-close from the filing's session.
How to read this document
| Where a broker report shows | This document shows | Why |
|---|---|---|
| A rating (BUY / ADD / REDUCE / SELL) | A state: the latest filed quarter and the measured reactions | an event is a fact; a rating is an opinion that requires SEBI RA registration |
| A target price and upside | The current price and the multiples against the group | a target is a forecast; a multiple is a measurement |
| Estimate years marked E | More audited years; no estimates | MarketPing publishes no forecasts — your own model lives on the Models page |
Sources, method and disclosures
This document is a statistical summary of publicly filed information and market data, prepared by software from primary sources: SEBI results XBRL filed with BSE and NSE, LODR disclosures, shareholding patterns, exchange price data. It contains no research recommendation, no price target and no opinion on the merits of any security, and is not a research report within the meaning of the SEBI (Research Analysts) Regulations, 2014, Regulation 2(1)(w)(vii). Financial statements are as filed (consolidated where the company files consolidated results). Ratios are computed over filed lines. Where a figure is unavailable the table shows a dash rather than an estimate. The business brief is written by MarketPing's reader from the annual report and checked against it; no figure in a table was generated by a model. Nothing here constitutes investment advice, an offer or a solicitation; readers should consult a SEBI-registered adviser before acting. MarketPing is not a SEBI-registered intermediary.
Every figure is a filed number or a ratio over filed numbers · No rating, target or fair value is expressed · Disclosures on the last pagemarketping.in